NDAORALTABLETPriority Review
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
4/8 — Partial
Priority Review
REVUFORJ (revumenib) by Syndax Pharmaceuticals. Approved for acute myeloid leukemia. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (12)
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Started May 2026
20 enrolled
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Started Nov 2025
468 enrolled
Acute Myeloid Leukemias
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Started Mar 2025
415 enrolled
Acute Myeloid Leukemia, Adult
Revumenib in Combination With 7+3 + Midostaurin in AML
Started Dec 2024
22 enrolled
Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Started Sep 2024
8 enrolled
Acute Myeloid Leukemia
Worked on REVUFORJ at Syndax Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.